Metformine Biogaran (Metformin Hydrochloride)

Metformin primarily inhibits mitochondrial complex I, which reduces hepatic gluconeogenesis. It also activates AMP‑activated protein kinase (AMPK), leading to increased peripheral glucose uptake and decreased intestinal glucose absorption, collectively lowering blood glucose concentrations.

The specific dose of Metformine Biogaran is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Metformine Biogaran is classified as pregnancy category B, indicating that animal studies have not shown risk but there are limited human data. It may be used during pregnancy only if the potential benefit justifies the potential risk. Metformin is excreted in breast milk; breastfeeding decisions should be made in consultation with a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any required import documentation.

Metformine Biogaran belongs to the biguanide class, which differs from sulfonylureas, DPP‑4 inhibitors, or SGLT2 inhibitors. Unlike insulin‑secretagogues, metformin does not stimulate insulin release, reducing the risk of hypoglycaemia when used alone. It also offers benefits such as modest weight loss and potential cardiovascular protection, making it a first‑line therapy in many guidelines.

Metformine Biogaran should be stored at ambient temperature, below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Metformine Biogaran is taken orally, usually with meals to minimise gastrointestinal discomfort. The tablets are swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional.

The most serious adverse reaction is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal impairment, hepatic disease, or excessive alcohol intake. Prompt medical attention is required if symptoms such as unexplained fatigue, rapid breathing, or abdominal pain develop.

Metformine Biogaran is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin, acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in those with severe hepatic disease. It should also be used with caution in elderly patients and those with heart failure.